The APOO knockout Jurkat polyclonal cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphoblast cell line, designed for loss-of-function studies of the APOO gene encoding a mitochondrial apolipoprotein. This product comprises a heterogeneous pool of Jurkat cells harboring targeted disruptions of APOO, generated via CRISPR/Cas9-mediated gene editing without clonal isolation, providing a robust model to investigate mitochondrial complex integrity and metabolic adaptation in a T-cell acute lymphoblastic leukemia background.
The Jurkat parental cell line is an immortalized human T-cell leukemia line originally established from the peripheral blood of a 14-year-old male with T-cell acute lymphoblastic leukemia. These cells serve as a widely utilized model for T-cell receptor signaling, immunological synapse formation, and leukemogenesis, exhibiting characteristic T-lymphoblast features including CD3 and CD28 surface expression. Their adaptability to gene editing and functional assays makes them a preferred platform for cancer metabolism and immunology research.
APOO encodes a constituent of the mitochondrial contact site and cristae organizing system (MICOS) complex, essential for the maintenance of cristae junction architecture and inner membrane organization. Within the MICOS complex, APOO interacts directly with core scaffold proteins such as IMMT (MIC60) and CHCHD3 (MIC19), as well as the MIC10, MIC25, and MIC27 subunits, to stabilize cristae ultrastructure and optimize oxidative phosphorylation efficiency. The expression and turnover of APOO are transcriptionally regulated by upstream factors including PPARGC1A (PGC-1??), HIF1A, NRF1, and TFAM, linking mitochondrial biogenesis programs to cellular energy demand. Disruption of APOO leads to downstream impairment of MICOS complex assembly, loss of mitochondrial membrane potential, reduced ATP production, elevated reactive oxygen species levels, and altered cytochrome c release, thereby sensitizing cells to intrinsic apoptosis pathways.
In the context of Jurkat T-lymphoblasts, APOO loss-of-function provides a unique tool to dissect how mitochondrial cristae dynamics influence T-cell metabolic reprogramming and survival signals. Jurkat cells rely on mitochondrial respiration for activation-induced proliferation and effector function, and APOO-dependent cristae organization is hypothesized to modulate the balance between glycolysis and oxidative phosphorylation during oncogenic transformation. Consequently, this knockout model facilitates exploration of mitochondrial contributions to T-cell acute lymphoblastic leukemia pathogenesis, including apoptosis resistance mechanisms and metabolic vulnerabilities that may be exploited for therapy.
These APOO knockout polyclonal cells are suited for a broad spectrum of functional applications, including Western blotting and co-immunoprecipitation to assess MICOS complex integrity, RT-qPCR profiling of mitochondrial biogenesis genes (e.g., PPARGC1A, NRF1, TFAM), Seahorse metabolic flux analysis to quantify oxygen consumption rates, and flow cytometry using TMRE or JC-1 to measure mitochondrial membrane potential. Further studies may incorporate apoptosis assays via Annexin V/PI staining, electron microscopy to visualize cristae ultrastructure defects, T-cell activation assays with CD3/CD28 costimulation, and reactive oxygen species detection using CellROX probes. For additional technical specifications, validation data, or ordering details, please contact Ascent Research.
